{
  "source": "PA-Notification-Tykerb.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1112-12\nProgram Prior Authorization/Notification\nMedication Tykerb® (lapatinib)\nP&T Approval Date 8/2008, 6/2009, 9/2010, 12/2010, 9/2011, 8/2012, 7/2013, 11/2014,\n11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 10/2021, 10/2022,\n10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nTykerb (lapatinib) is a kinase inhibitor indicated for use in combination with Femara® (letrozole)\nfor the treatment of postmenopausal women with hormone receptor positive metastatic breast\ncancer that overexpresses the human epidermal growth factor receptor 2 (HER2) receptor for\nwhom hormonal therapy is indicated. Tykerb is also indicated in combination with Xeloda®\n(capecitabine) for treatment of patients with advanced or metastatic breast cancer whose tumors\noverexpress HER2 and who have received prior therapy, including an anthracycline, a taxane, and\ntrastuzumab. Patients should have disease progression on trastuzumab prior to initiation of\ntreatment with Tykerb in combination with Xeloda. The National Cancer Comprehensive Network\n(NCCN) also recommends the use of Tykerb in metastatic central nervous system (CNS) lesions\nwith primary tumor of the breast, intracranial and spinal ependymomas, EGFR-positive chordoma,\nand colon and rectal cancers not previously treated with HER2 inhibitors.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Tykerb will be approved based on the following criterion:\na. Patient is less tha",
    "n the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Tykerb will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Breast Cancer\n1. Initial Authorization\na. Tykerb will be approved based on one of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) All of the following:\n(a) Diagnosis of recurrent unresectable (local or regional) or stage IV breast\ncancer\n-AND-\n(b) Disease is hormone receptor positive and human epidermal growth factor\nreceptor 2-positive (HER2+)\n-AND-\n(c) Used in combination with an aromatase inhibitor [e.g., Aromasin\n(exemestane), Femara (letrozole), Arimidex (anastrozole)]\n-OR-\n(2) All of the following:\n(a) One of the following:\ni. Diagnosis of recurrent unresectable (local or regional) or stage IV breast\ncancer\nii. Breast cancer that is unresponsive to preoperative systemic therapy\n-AND-\n(b) Disease is HER2+\n-AND-\n(c) Used as fourth line therapy and beyond in combination with one of the\nfollowing:\ni. Herceptin (trastuzumab)\nii. Xeloda (capecitabine)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tykerb will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tykerb therapy\nAuthorization will be issued for 12 months.\nC. Central Nervous System (CNS) Cancers\n1. Initial Authorization\n© 2024 UnitedHealthcare Services, Inc.\n2\na. Tykerb will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of recurrent, central nervous system (CNS) cancer with metastatic\nlesions\n-AND-\n(b) Tykerb is active against primary (breast) tumor\n-AND-\n(c) Used in combination with Xeloda (capecitabine)\n-OR-\n(2) All of the following:\n(a) Diagnosis of progressive or recurrent intracranial or spinal ependymoma\n(excluding subependymoma)\n-AND-\n(b) Patient has received previous radiation therapy\n-AND-\n(",
    ")\n-OR-\n(2) All of the following:\n(a) Diagnosis of progressive or recurrent intracranial or spinal ependymoma\n(excluding subependymoma)\n-AND-\n(b) Patient has received previous radiation therapy\n-AND-\n(c) One of the following:\ni. Patient has received gross total or subtotal resection with negative\ncerebrospinal fluid (CSF) cytology\nii. Patient has received subtotal resection and evidence of metastasis\n(brain, spine, or CSF)\niii. Patient has unresectable disease\n-AND-\n(d) Used in combination with Temodar (temozolomide)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tykerb will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tykerb therapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n3\nD. Chordoma\n1. Initial Authorization\na. Tykerb will be approved based on both of the following criteria:\n(1) Diagnosis of recurrent conventional or chondroid chordoma\n-AND-\n(2) Disease is EGFR-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tykerb will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tykerb therapy\nAuthorization will be issued for 12 months.\nE. Colon Cancer\n1. Initial Authorization\na. Tykerb will be approved based on all of the following criteria:\n(1) Diagnosis of colon cancer\n-AND-\n(2) Disease is HER2-amplified and RAS and BRAF wild-type\n-AND-\n(3) One of the following:\n(a) Disease is proficient mismatch repair/microsatellite-stable (pMMR/MSS)\n-OR-\n(b) Both of the following:\ni. Disease is positive for deficient mismatch repair/microsatellite\ninstability-high (dMMR/MSI-H) or polymerase epsilon/delta\n(POLE/POLD1) mutation\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n4\nii. One of the following:\n• Ineligible for or progressed on checkpoint inhibitor immunotherapy\n[e.g., Opdivo (nivolumab), Keytruda (pembrolizumab), Jemperli\n(dostarlimab-gxly)]\n• Has a contraindicatio",
    "ii. One of the following:\n• Ineligible for or progressed on checkpoint inhibitor immunotherapy\n[e.g., Opdivo (nivolumab), Keytruda (pembrolizumab), Jemperli\n(dostarlimab-gxly)]\n• Has a contraindication to checkpoint inhibitor immunotherapy\n-AND-\n(4) One of the following:\n(a) Both of the following:\ni. Used as initial therapy for unresectable metachronous metastases\nii. Previous therapy with FOLFOX (fluorouracil, leucovorin, and\noxaliplatin) or CapeOX (capecitabine and oxaliplatin) within the past 12\nmonths\n-OR-\n(b) Intensive chemotherapy with one of the following is not recommended:\ni. Oxaliplatin\nii. Irinotecan\niii. Capecitabine\n-OR-\n(c) Used as second-line and subsequent therapy for progression of advanced or\nmetastatic disease\n-AND-\n(5) Used in combination with trastuzumab\n-AND-\n(6) Patient has not previously been treated with a HER2 inhibitor [e.g.,\ntrastuzumab, Perjeta (pertuzumab), Nerlynx (neratinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tykerb will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tykerb therapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n5\nF. Rectal Cancer\n1. Initial Authorization\na. Tykerb will be approved based on all of the following criteria:\n(1) Diagnosis of rectal cancer\n-AND-\n(2) Disease is HER2-amplified and RAS and BRAF wild-type\n-AND-\n(3) One of the following:\n(a) Disease is proficient mismatch repair/microsatellite-stable (pMMR/MSS)\n-OR-\n(b) Disease is positive for deficient mismatch repair/microsatellite instability-\nhigh (dMMR/MSI-H) or polymerase epsilon/delta (POLE/POLD1)\nmutation and one of the following:\ni. Ineligible for or progressed on checkpoint inhibitor immunotherapy\n[e.g., Opdivo (nivolumab), Keytruda (pembrolizumab), Jemperli\n(dostarlimab-gxly)]\nii. Has a contraindication to checkpoint inhibitor immunotherapy\n-AND-\n(4) One of the following:\n(a) Both of the following:\ni. Used as initial th",
    "Keytruda (pembrolizumab), Jemperli\n(dostarlimab-gxly)]\nii. Has a contraindication to checkpoint inhibitor immunotherapy\n-AND-\n(4) One of the following:\n(a) Both of the following:\ni. Used as initial therapy for unresectable metachronous metastases\nii. Previous therapy with FOLFOX (fluorouracil, leucovorin, and\noxaliplatin) or CapeOX (capecitabine and oxaliplatin) within the past 12\nmonths\n-OR-\n(b) Intensive chemotherapy with one of the following is not recommended:\ni. Oxaliplatin\nii. Irinotecan\niii. capecitabine\n-OR-\n© 2024 UnitedHealthcare Services, Inc.\n6\n(c) Used as second-line and subsequent therapy for progression of advanced or\nmetastatic disease\n-AND-\n(5) Used in combination with trastuzumab\n-AND-\n(6) Patient has not previously been treated with a HER2 inhibitor [e.g.,\ntrastuzumab, Perjeta (pertuzumab), Nerlynx (neratinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tykerb will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tykerb therapy\nAuthorization will be issued for 12 months.\nG. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limit may be in place.\n4. References:\n1. Tykerb [package insert]. East Hanover, NJ: Novartis",
    "c. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limit may be in place.\n4. References:\n1. Tykerb [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; March 2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org. Accessed August 28, 2024.\n© 2024 UnitedHealthcare Services, Inc.\n7\nProgram Prior Authorization/Notification –Tykerb® (lapatinib)\nChange Control\n11/2014 Annual review. Added coverage criteria for chordoma. Updated\nbackground & references.\n11/2015 Annual review. Increased authorization from 7 months to 12 months.\nRevised breast cancer & CNS cancer criteria. Updated background &\nreferences.\n9/2016 Annual review. Changed Member to Patient. Revised breast cancer\ncriteria. Updated references.\n9/2017 Annual review. Updated references.\n9/2018 Annual review. Updated coverage criteria for breast cancer. Updated\nreferences.\n9/2019 Annual review. Updated coverage criteria to align with NCCN\nguidelines. Updated references. Added general NCCN recommended\nreview criteria.\n9/2020 Annual review. No changes to coverage criteria.\n10/2021 Annual review. Updated coverage criteria for rectal cancer to align with\nNCCN guidelines. Updated references.\n10/2022 Annual review. Updated coverage criteria for colon cancer to align with\nNCCN guidelines. Added state mandate. Updated references.\n10/2023 Annual review. Updated coverage criteria for colon cancer.\n10/2024 Annual review. Updated coverage criteria for breast cancer, central\nnervous system cancers, chordoma, colon cancer, and rectal cancer per\nNCCN guidelines.\n© 2024 UnitedHealthcare Services, Inc.\n8"
  ]
}